This federal contract award, valued at $49,748.73, was issued by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 2 (VISN 2) to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices. The contract is for the provision of Novocure's Optune line of Tumor Treating Fields (TTFields) therapy devices, transducer arrays, rental equipment, and associated support services. This contract does not utilize any set-aside designations and is being delivered under Novocure's existing 5-year, $28.85 million Federal Supply Schedule (FSS) contract with the VA VHA, which was awarded in November 2022. The primary funding agency is the VA VHA, and the contract supports the agency's mission of expanding veterans' access to cutting-edge cancer therapies by enabling VA facilities nationwide to offer Novocure's non-invasive treatment option to veteran patients diagnosed with glioblastoma, mesothelioma, and other forms of solid tumor cancers.
Generated 3/29/25, 10:06 AM